Oculis (OCS) AGM 2026 summary

Opening remarks and agenda

• Meeting convened in compliance with statutory notice and agenda published in the Swiss Official Gazette of Commerce on April 21, 2026.

• All formalities fulfilled, meeting declared open with no objections raised.

• Secretary, vote counter, auditors, independent proxy, and notary introduced; voting procedures explained.

Financial performance review

• 2025 marked as a successful and transformational year with three advanced-stage candidates in the pipeline.

• Strong balance sheet with no debt and cash runway into H1 2029, excluding a CHF 100 million loan facility.

• Cash position at end of 2025 was CHF 213 million, up from CHF 98.7 million in 2024, mainly due to $210 million equity financing.

• R&D expenses accounted for nearly 70% of total operating expenses, driving a net loss of CHF 99 million in 2025.

• Operating expenses increased due to DIAMOND phase III trials and personnel costs.

Board and executive committee updates

• Board members and director nominee present; all board and executive committee members proposed for re-election or election.

• Senior management team expanded to support clinical stage asset delivery.